var data={"title":"Uridine triacetate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Uridine triacetate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/391210?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=uridine-triacetate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Uridine triacetate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=uridine-triacetate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Uridine triacetate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46170543\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Vistogard;</li>\n      <li>Xuriden</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7976689\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote;</li>\n      <li>\n        Endocrine and Metabolic Agent, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7976696\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fluoropyrimidine overdose/overexposure:</b> Oral: 10 g every 6 hours for 20 doses beginning as soon as possible after overdose or early-onset toxicity within 96 hours after the end of fluorouracil or capecitabine administration (Bamat 2013; von Borstel 2009). Administer the full course of 20 doses, even if the patient appears or feels well.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hereditary orotic aciduria:</b> Oral: Initial: 60 mg/kg once daily; increase to 120 mg/kg (maximum: 8 g) for insufficient efficacy (eg, urine orotic acid levels remaining above normal or increasing above the usual/expected range for the patient; lab values affected by orotic acid [red or white blood cell indices] worsening; worsening disease signs/symptoms).</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Uridine Triacetate Daily Dose for Hereditary Orotic Aciduria Based on Weight (kg)</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Patient weight</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">60 mg/kg<sup>1</sup> dose</p>\n            <p style=\"text-indent:0em;\">Dose in grams</p>\n            <p style=\"text-indent:0em;\">(dose in teaspoons<sup>2</sup>)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">120 mg/kg<sup>1</sup> dose</p>\n            <p style=\"text-indent:0em;\">Dose in grams</p>\n            <p style=\"text-indent:0em;\">(dose in teaspoons<sup>2</sup>)</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"3\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <b>Note:</b> One packet contains uridine triacetate 2 g. </p></td></tr>\n        <tr>\n          <td colspan=\"3\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <sup>1</sup>Doses rounded (by the manufacturer) by weight category to achieve approximate dose level</p></td></tr>\n        <tr>\n          <td colspan=\"3\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <sup>2</sup>A  2 gram uridine triacetate (Xuriden) packet contains approximately <sup>3</sup>/<sub>4</sub> tsp</p></td></tr></tfoot>\n      <tbody valign=\"top\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&le;5 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.4 g</p>\n            <p style=\"text-indent:0em;\"> (<sup>1</sup>/<sub>8</sub> tsp)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.8 g </p>\n            <p style=\"text-indent:0em;\">(<sup>1</sup>/<sub>4</sub> tsp)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 to 10 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.4 to 0.6 g </p>\n            <p style=\"text-indent:0em;\">(<sup>1</sup>/<sub>4</sub> tsp)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.8 to 1.2 g </p>\n            <p style=\"text-indent:0em;\">(<sup>1</sup>/<sub>2</sub> tsp) </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">11 to 15 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.7 to 0.9 g </p>\n            <p style=\"text-indent:0em;\">(<sup>1</sup>/<sub>2</sub> tsp)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.4 to 1.8 g </p>\n            <p style=\"text-indent:0em;\">(<sup>3</sup>/<sub>4</sub> tsp or 1 entire packet) </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">16 to 20 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 1.2 g </p>\n            <p style=\"text-indent:0em;\">(<sup>1</sup>/<sub>2</sub> tsp)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 to 2.4 g</p>\n            <p style=\"text-indent:0em;\">(1 tsp)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">21 to 25 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.3 to 1.5 g </p>\n            <p style=\"text-indent:0em;\">(<sup>1</sup>/<sub>2</sub> tsp)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.6 to 3 g</p>\n            <p style=\"text-indent:0em;\">(1 tsp)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">26 to 30 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.6 to 1.8 g </p>\n            <p style=\"text-indent:0em;\">(<sup>3</sup>/<sub>4</sub> tsp or 1 entire packet)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3.2 to 3.6 g </p>\n            <p style=\"text-indent:0em;\">(1<sup>1</sup>/<sub>4</sub> tsp)  </p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">31 to 35 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.9 to 2.1 g </p>\n            <p style=\"text-indent:0em;\">(<sup>3</sup>/<sub>4</sub> tsp or 1 entire packet)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3.8 to 4.2 g </p>\n            <p style=\"text-indent:0em;\">(1<sup>1</sup>/<sub>2</sub> tsp or 2 entire packets)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">36 to 40 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.2 to 2.4 g</p>\n            <p style=\"text-indent:0em;\">(1 tsp)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.4 to 4.8 g </p>\n            <p style=\"text-indent:0em;\">(1<sup>3</sup>/<sub>4</sub> tsp)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">41 to 45 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5 to 2.7 g</p>\n            <p style=\"text-indent:0em;\">(1 tsp)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 to 5.4 g</p>\n            <p style=\"text-indent:0em;\">(2 tsp or 3 entire packets)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">46 to 50 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.8 to 3 g</p>\n            <p style=\"text-indent:0em;\">(1 tsp)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.6 to 6 g</p>\n            <p style=\"text-indent:0em;\">(2 tsp or 3 entire packets)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">51 to 55 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3.1 to 3.3 g </p>\n            <p style=\"text-indent:0em;\">(1<sup>1</sup>/<sub>4</sub> tsp)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6.2 to 6.6 g </p>\n            <p style=\"text-indent:0em;\">(2<sup>1</sup>/<sub>4</sub> tsp)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">56 to 60 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3.4 to 3.6 g </p>\n            <p style=\"text-indent:0em;\">(1<sup>1</sup>/<sub>4</sub> tsp)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6.8 to 7.2 g </p>\n            <p style=\"text-indent:0em;\">(2<sup>1</sup>/<sub>2</sub> tsp)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">61 to 65 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3.7 to 3.9 g </p>\n            <p style=\"text-indent:0em;\">(1<sup>1</sup>/<sub>2</sub> tsp or 2 entire packets)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.4 to 7.8 g </p>\n            <p style=\"text-indent:0em;\">(2<sup>1</sup>/<sub>2</sub> tsp)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">66 to 70 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4 to 4.2 g </p>\n            <p style=\"text-indent:0em;\">(1<sup>1</sup>/<sub>2</sub> tsp or 2 entire packets)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 g </p>\n            <p style=\"text-indent:0em;\">(2<sup>3</sup>/<sub>4</sub> tsp or 4 entire packets)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">71 to 75 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.3 to 4.5 g </p>\n            <p style=\"text-indent:0em;\">(1<sup>1</sup>/<sub>2</sub> tsp or 2 entire packets)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 g </p>\n            <p style=\"text-indent:0em;\">(2<sup>3</sup>/<sub>4</sub> tsp or 4 entire packets)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;75 kg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 g</p>\n            <p style=\"text-indent:0em;\">(2 tsp or 3 entire packets)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 g </p>\n            <p style=\"text-indent:0em;\">(2<sup>3</sup>/<sub>4</sub> tsp or 4 entire packets)</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45069133\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=uridine-triacetate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Uridine triacetate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fluoropyrimidine overdose/overexposure: </b> Oral: 6.2 g/m<sup>2</sup> (maximum: 10 g/dose) every 6 hours for 20 doses beginning as soon as possible after overdose or early-onset toxicity within 96 hours after the end of fluorouracil or capecitabine administration. Administer the full course of 20 doses, even if the patient appears or feels well.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Uridine Triacetate Pediatric Dose for Fluoropyrimidine Overdose/Overexposure Based on Body Surface Area (BSA; m<sup>2</sup>) </caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Patient BSA </p></th>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Uridine Triacetate 6.2 g/m<sup>2</sup>/dose<sup>a</sup></p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dose in grams</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dose in graduated teaspoons</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"3\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <b>Note:</b> One Vistogard packet contains uridine triacetate 10 g. </p></td></tr>\n        <tr>\n          <td colspan=\"3\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <sup>a</sup>Doses rounded by BSA to achieve approximate dose; each dose is administered every 6 hours for 20 doses.  </p></td></tr></tfoot>\n      <tbody valign=\"top\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.34 to 0.44 m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.1 to 2.7 g</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 tsp</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.45 to 0.55 m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.8 to 3.4 g </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1  <sup>1</sup>/<sub>4</sub> tsp</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.56 to 0.66 m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3.5 to 4.1 g </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1  <sup>1</sup>/<sub>2</sub> tsp</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.67 to 0.77 m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.2 to 4.8 g </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1  <sup>3</sup>/<sub>4</sub> tsp</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.78 to 0.88 m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4.9 to 5.4 g </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 tsp</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.89 to 0.99 m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.5 to 6.1 g </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2  <sup>1</sup>/<sub>4</sub> tsp</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 1.1 m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6.2 to 6.8 g </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2  <sup>1</sup>/<sub>2</sub> tsp</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.11 to 1.21 m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6.9 to 7.5 g</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 <sup>3</sup>/<sub>4</sub> tsp</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.22 to 1.32 m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.6 to 8.1 g</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 tsp</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.33 to 1.43 m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8.2 to 8.8 g</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 <sup>1</sup>/<sub>4</sub> tsp</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;1.44  m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 g </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 full packet</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hereditary orotic aciduria:</b> Infants, Children, and Adolescents: Oral: Refer to adult dosing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7976697\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45069134\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45069135\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46170544\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vistogard: 10 g (4 ea, 20 ea) [orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xuriden: 2 g (1 ea, 30 ea) [orange flavor]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46170542\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11234389\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Fluorouracil accidental overdose/overexposure: Uridine triacetate (formerly called vistonuridine) is available through select specialty pharmacies. Procurement information is available from Wellstat Therapeutics at 1-800-914-0071 or https://www.vistogard.com/Professional/How-to-Order.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7976698\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Granules: Measure the prescribed dose using either a scale accurate to at least 0.1 gram, or a graduated teaspoon, accurate to the fraction of the dose to be administered (accurate to <sup>1</sup>/<sub>4</sub> teaspoonful). Discard the unused portion of granule packet after measuring out the dose. Do not chew granules. May be administered without regard to meals (food does not have an effect on uridine exposure).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluoropyrimidine overdose/overexposure:  Administer orally; begin as soon as possible after overdose or early-onset toxicity within 96 hours following the end of fluorouracil or capecitabine overdose/overexposure (Bamat 2013; von Borstel 2009). Administer within 30 minutes of preparation (in soft food such as applesauce, pudding, or yogurt), followed by at least 120 mL water. If patient vomits within 2 hours of taking dose, administer another complete dose as soon as possible after vomiting episode. If a dose is missed, administer the missed dose as soon as possible and then administer the next dose at the regularly scheduled time. If necessary to administer through a nasogastric or gastrostomy tube (due to stomatitis or mucositis), mix with thickening agent (see Preparation for Administration); following administration, flush tube with water. Administer the full treatment course (all 20 doses), even if the patient appears or feels well.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hereditary orotic aciduria:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Administration with food:</i> May be mixed in food (ie, 3 to 4 ounces of applesauce, pudding, or yogurt) and administered immediately, followed by drinking at least 120 mL water. Do not chew the granules. Do not save for later use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Administration in milk or infant formula:</i> May be mixed with milk or infant formula for patients receiving a dose of up to 2 grams (<sup>3</sup>/<sub>4</sub> teaspoon). See Preparation for Administration for oral syringe preparation instructions. Place the tip of the oral syringe in the patient&rsquo;s mouth between the cheek and gum at the back of the mouth. Gently push the plunger all the way down. Refill the syringe with another 5 mL of milk/infant formula. Gently swirl the syringe to rinse remaining uridine triacetate granules from the syringe barrel. Place the tip of the syringe in the patient&rsquo;s mouth between the cheek and gum at the back of the mouth. Gently push the plunger all the way down. May follow with a bottle of milk or infant formula.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45069164\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hereditary orotic aciduria:</b> Treatment of hereditary orotic aciduria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fluoropyrimidine overdose/overexposure:</b> Emergency treatment of fluorouracil or capecitabine overdose (regardless of the presence of symptoms) or early-onset severe or life-threatening cardiac or CNS toxicity and/or early-onset unusually severe adverse reactions (eg, GI toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration (in pediatrics and adults). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Uridine triacetate is not recommended for nonemergent treatment of adverse reactions associated with fluorouracil or capecitabine (because it may diminish efficacy of these medications). Safety and efficacy of uridine triacetate initiated more than 96 hours following the end of fluorouracil or capecitabine administration have not been established. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44661391\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;margin-right:2em;\">1% to 10%</p>\n    <p style=\"text-indent:2em;margin-right:4em;\">Gastrointestinal: Vomiting (10%), nausea (5%), diarrhea (3%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45069168\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45069169\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:0em;display:inline\">There are no warnings listed in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300196\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8018477\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9537&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45069166\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Information related to the use of uridine triacetate for the treatment of hereditary orotic aciduria and fluoropyrimidine overdose/severe (life-threatening) toxicity during pregnancy is limited; monitor closely, dose adjustments may be required (Bensen 1991). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45069167\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if uridine triacetate is excreted into breast milk. According to the manufacturer, the decision to breast-feed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7976700\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Fluoropyrimidine overdose/overexposure: CBC with differential; gastrointestinal toxicity (Hidalgo 2000).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7976691\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Uridine triacetate is an acetylated form of uridine which is deacetylated following administration to provide circulating uridine in patients with hereditary orotic aciduria. In patients with fluorouracil overdose or overexposure, uridine triacetate is a direct chemical antagonist against fluorouracil toxicity (Bamat 2013). Uridine reduces incorporation of fluorouridine triphosphate (FUTP; a fluorouracil metabolite) into RNA of hematopoietic progenitor cells and gastrointestinal mucosal cells to reduce fluorouracil toxicity in normal tissues (Hidalgo 2000).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7976693\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: Hereditary orotic aciduria: Oral exogenous uridine improves hematologic abnormalities within 2 to 3 weeks; urinary orotic acid reduced within 1 to 2 weeks of initiating therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of action: Hereditary orotic aciduria: Hematologic abnormalities and orotic aciduria return within days up to 2 to 3 weeks after discontinuation or dose reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Distributes into cells; crosses the blood brain barrier</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Deacetylated (by nonspecific esterases) to uridine and free acetate (Hidalgo 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 2 to 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine; also catabolic metabolism in tissues.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46251911\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Vistogard Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 g (4): $19,262.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Xuriden Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 g (1): $900.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/uridine-triacetate-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bamat MK, Tremmel R, von Borstel R, et al. Clinical experience with uridine triacetate for 5-FU overexposure: an update [abstract e20592 from 2013 ASCO Annual Meeting]. <i>J Clin Oncol</i>. 2013;31(18s):e20592.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bensen JT, Nelson LH, Pettenati MJ, et al. First report of management and outcome of pregnancies associated with hereditary orotic aciduria. <i>Am J Med Genet</i>. 1991;41(4):426-431.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/uridine-triacetate-drug-information/abstract-text/1776631/pubmed\" target=\"_blank\" id=\"1776631\">1776631</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hidalgo M, Villalona-Calero MA, Eckhardt SG, et al, &ldquo;Phase I and Pharmacologic Study of PN401 and Fluorouracil in Patients With Advanced Solid Malignancies,&rdquo; <i>J Clin Oncol</i>, 2000, 18(1):167-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/uridine-triacetate-drug-information/abstract-text/10623707/pubmed\" target=\"_blank\" id=\"10623707\">10623707</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vistogard (uridine triacetate) [prescribing information]. Rockville, MD: Wellstat Therapeutics Corporation; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    von Borstel R, O&rsquo;Neil J, and Bamat M, &ldquo;Vistonuridine: An Orally Administered, Life-Saving Antidote for 5-Fluorouracil (5FU) Overdose,&rdquo; <i>J Clin Oncol</i>, 2009, 27(15S):9616 [abstract 9616 from 2009 ASCO Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xuriden (uridine triacetate) [prescribing information]. Gaithersburg, MD; Wellstat Therapeutics Corporation; September 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9537 Version 69.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F46170543\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F7976689\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F7976696\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F45069133\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F7976697\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F45069134\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F45069135\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F46170544\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F46170542\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11234389\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F7976698\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45069164\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F44661391\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45069168\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F45069169\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300196\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8018477\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F45069166\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F45069167\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F7976700\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7976691\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F7976693\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F46251911\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9537|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=uridine-triacetate-patient-drug-information\" class=\"drug drug_patient\">Uridine triacetate: Patient drug information</a></li><li><a href=\"topic.htm?path=uridine-triacetate-pediatric-drug-information\" class=\"drug drug_pediatric\">Uridine triacetate: Pediatric drug information</a></li></ul></div></div>","javascript":null}